{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:03Z","timestamp":1791908163430,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T00:00:00Z","timestamp":1471392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Antibodies inhibiting the programmed death receptor 1 (PD\u20101) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD\u20101 blockade in patients with uveal melanoma has not been well characterized.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Fifty\u2010eight patients with stage IV uveal melanoma received PD\u20101 or PD\u20101 ligand (PD\u2010L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression\u2010free survival (PFS), and overall survival (OS), were retrospectively determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty\u2010eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%\u201022.5%). Stable disease (\u22656 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4\u20102.8 months), and the median OS was 7.6 months (95% CI, 0.7\u201014.6 months). There was no association between prior treatment with ipilimumab or liver\u2010directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>PD\u20101 and PD\u2010L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. <jats:bold><jats:italic>Cancer<\/jats:italic> 2016;122:3344\u20133353<\/jats:bold>. \u00a9 <jats:italic>2016 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30258","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T11:07:57Z","timestamp":1471432077000},"page":"3344-3353","source":"Crossref","is-referenced-by-count":364,"title":["Clinical outcomes in metastatic uveal melanoma treated with PD\u20101 and PD\u2010L1 antibodies"],"prefix":"10.1002","volume":"122","author":[{"given":"Alain P.","family":"Algazi","sequence":"first","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy K.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo R.","family":"Munhoz","sequence":"additional","affiliation":[{"name":"Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Piulats","sequence":"additional","affiliation":[{"name":"Spanish Melanoma Multidisciplinary Group Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt\u2010Ingram Cancer Center Vanderbilt University Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Hwang","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil I.","family":"Daud","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[{"name":"Vanderbilt\u2010Ingram Cancer Center Vanderbilt University Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[{"name":"Johansson Comprehensive Cancer Center University of California Los Angeles, Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Postow","sequence":"additional","affiliation":[{"name":"Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[{"name":"Isaac Perlmutter Cancer Center, NYU Langone Medical Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,17]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1","article-title":"Epidemiology of tumors affecting the visual system","volume":"3","author":"Marshall EC","year":"1993","journal-title":"Optom Clin"},{"key":"e_1_2_8_3_1","unstructured":"Cancer.Net American Society of Clinical Oncology. Eye Cancer: Statistics. Available at:http:\/\/www.cancer.net\/cancer-types\/eye-cancer\/statistics. Accessed October 20 2015."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.1.54"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2452"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000584"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07586"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6534"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2219::AID-CNCR2820720725>3.0.CO;2-J"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.023"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6096"},{"key":"e_1_2_8_12_1","unstructured":"AstraZeneca. AstraZeneca provides update on selumetinib in uveal melanoma [press release]. Available at:https:\/\/www.astrazeneca.com\/our-company\/media-centre\/press-releases\/2015\/astrazeneca-selumetinib-uveal-melanoma-oncology-22072015.html. Accessed November 11 2015."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"issue":"15","key":"e_1_2_8_16_1","article-title":"Updated survival results from a randomized, dose\u2010ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) [abstract]","volume":"33","author":"Plimack ER","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1200\/jco.2014.32.15_suppl.6011","article-title":"A phase Ib study of MK\u20103475 in patients with human papillomavirus (HPV)\u2010associated and non\u2010HPV\u2013associated head and neck (H\/N) cancer [abstract]","volume":"32","author":"Seiwert TY","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.290.290"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28282"},{"issue":"15","key":"e_1_2_8_27_1","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma [abstract]","author":"Kottschade LA","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_29_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0","author":"National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program (CTEP)","year":"2010"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_8_34_1","unstructured":"ClinicalTrials.gov.Pembrolizumab in Treating Patients With Advanced Uveal Melanoma\u2010Full Text View. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02359851?term=pembrolizumab+AND+uveal&rank=1. Accessed April 6 2016."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130142"},{"key":"e_1_2_8_36_1","unstructured":"Quest Diagnostics. Quest Diagnostics Introduces Dako's PD\u2010L1 Companion Diagnostic for KEYTRUDA Merck's Anti\u2010PD\u20101 Therapy for Metastatic Non\u2010Small Cell Lung Cancer Whose Tumors Express PD\u2010L1 with Disease Progression On or After Platinum\u2010Containing Chemotherapy [press release]. Available at:http:\/\/www.prnewswire.com\/news-releases\/quest-diagnostics-introduces-dakos-pd-l1-companion-diagnostic-for-keytruda-mercks-anti-pd-1-therapy-for-metastatic-non-small-cell-lung-cancer-whose-tumors-express-pd-l1-with-disease-progression-on-or-after-platinum-containing-300153548.html. Accessed October 26 2015."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0330"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.08.020"},{"issue":"15","key":"e_1_2_8_42_1","article-title":"Clinical characteristics predictive of response to pembrolizumab in advanced melanoma [abstract]","volume":"33","author":"Tsai KK","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30258","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:08:49Z","timestamp":1760288929000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,17]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/cncr.30258"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30258","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,17]]}}}